Umbilical tissue compositions and methods of use

Abstract

Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.

1 . A method of repairing damaged tissue, the method comprising applying a composition comprising an amniotic epithelial layer from an umbilical cord to the damaged tissue, wherein the damaged tissue is soft tissue, wherein the composition does not contain blood vessels, and wherein the composition does not contain viable cells. 
     
     
         2 . The method of  claim 1 , wherein the composition does not contain a Wharton's jelly layer. 
     
     
         3 . The method of  claim 1 , wherein the composition is square-shaped. 
     
     
         4 . The method of  claim 1 , wherein the composition is flat. 
     
     
         5 . The method of  claim 1 , wherein the composition has a substantially uniform thickness. 
     
     
         6 . The method of  claim 1 , wherein the amniotic epithelial layer releases tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), hepatocyte growth factor (HGF), and transforming growth factor-beta 1 (TGF-β1) after being applied to the damaged tissue. 
     
     
         7 . The method of  claim 6 , wherein the amniotic epithelial layer further releases insulin-like growth factor 1 (IGF-1) after being applied to the damaged tissue. 
     
     
         8 . The method of  claim 1 , wherein the step of administering the composition to the damaged soft tissue comprises wrapping the damaged soft tissue with the composition. 
     
     
         9 . The method of  claim 8 , wherein the step of administering the composition to the damaged soft tissue further comprises securing the composition to the damaged soft tissue with sutures. 
     
     
         10 . The method of  claim 9 , wherein the sutures are polyglactin 910 (VICRYL®) sutures. 
     
     
         11 . The method of  claim 1 , wherein the damaged soft tissue is a ligament or a tendon. 
     
     
         12 . The method of  claim 11 , wherein the damaged soft tissue is a tendon, and the tendon is a torn tendon or a ruptured tendon. 
     
     
         13 . The method of  claim 11 , wherein the damaged soft tissue is a tendon, and the tendon is selected from an Achilles tendon, a peroneus brevis tendon, and a posterior tibial tendon. 
     
     
         14 . The method of  claim 11 , wherein the soft tissue is a ligament, and the ligament is a talofibular ligament. 
     
     
         15 . A method of attaching a composition comprising an amniotic epithelial layer from an umbilical cord to soft tissue of a subject, the method comprising attaching the composition comprising the amniotic epithelial layer to the soft tissue of the subject wherein the composition does not contain blood vessels and does not contain viable cells. 
     
     
         16 . The method of  claim 15 , wherein the composition does not contain a Wharton's jelly layer. 
     
     
         17 . The method of  claim 15 , wherein the composition is square-shaped. 
     
     
         18 . The method of  claim 15 , wherein the composition is flat. 
     
     
         19 . The method of  claim 15 , wherein the composition has a substantially uniform thickness. 
     
     
         20 . The method of  claim 15 , wherein the amniotic epithelial layer releases tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), hepatocyte growth factor (HGF), and transforming growth factor-beta 1 (TGF-β1) after being applied to the soft tissue. 
     
     
         21 . The method of  claim 20 , wherein the amniotic epithelial layer further releases insulin-like growth factor 1 (IGF-1) after being applied to the soft tissue. 
     
     
         22 . The method of  claim 15 , wherein the soft tissue is a ligament or a tendon. 
     
     
         23 . The method of  claim 22 , wherein the soft tissue is a tendon, and the tendon is a torn tendon or a ruptured tendon. 
     
     
         24 . The method of  claim 22 , wherein the soft tissue is a tendon, and the tendon is selected from an Achilles tendon, a peroneus brevis tendon, and a posterior tibial tendon. 
     
     
         25 . The method of  claim 22 , wherein the soft tissue is a ligament, and the ligament is a talofibular ligament. 
     
     
         26 . The method of  claim 15 , wherein the composition is attached to the soft tissue by wrapping the soft tissue with the composition. 
     
     
         27 . The method of  claim 15 , wherein the composition is attached to the soft tissue by securing the composition to the soft tissue with sutures. 
     
     
         28 . The method of  claim 27 , wherein the sutures are polyglactin 910 (VICRYL®) sutures.